Ribupatide
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 140
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Group 1: HRS9531 | n/r | n/r | n/r | n/r |
| Group 2: HRS9531placebo | n/r | n/r | n/r | n/r |
Not shown
- Group 1: HRS9531: endpoint not reported
- Group 2: HRS9531placebo: endpoint not reported